HER2 BATs

Small molecule

UUniversity of Virginia

HER2 BATs is one of 50 small molecule programs targeting Breast Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Voltaren

Novartis

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Zinecard

CChildren's Oncology Group

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1/2Active, not recruiting

Breast Cancer

NCT03272334

Q2 2032

Phase 1/2Not yet recruiting

Prostate Cancer

NCT07441889

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

Active, not recruiting·UUniversity of Virginia·Phase 1/2·NCT03272334·22 enrolled

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Terminated·UUniversity of Virginia·Phase 1·NCT03661424·3 enrolled

Prostate Cancer1 trial

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Not yet recruiting·UUniversity of Virginia·Phase 1/2·NCT07441889·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HER2 BATs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER2 BATs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER2 BATs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Virginia

HER2 BATs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q2 2032

Trials by Indication[1]

Breast Cancer2 trials

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News